The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a corticosteroid and long-acting beta-2 agonist indicated for the treatment of asthma and COPD.  The Propeller platform includes a sensor that is attached to the inhaler.... Read more

The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic... Read more

The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES. The post Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome appeared first on MPR.... Read more

The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES. The post Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome appeared first on MPR.... Read more

Treatment with ofatumumab (Novartis) was associated with a greater proportion of patients with relapsing forms of multiple sclerosis (RMS) achieving no evidence of disease activity (NEDA-3), compared with those who received teriflunomide, according to post hoc analysis of the phase 3 ASCLEPIOS trials. The post Ofatumumab Bests Teriflunomide in Halting... Read more

Treatment with ofatumumab (Novartis) was associated with a greater proportion of patients with relapsing forms of multiple sclerosis (RMS) achieving no evidence of disease activity (NEDA-3), compared with those who received teriflunomide, according to post hoc analysis of the phase 3 ASCLEPIOS trials. The post Ofatumumab Bests Teriflunomide in Halting... Read more

Positive topline data was announced from the phase 3 ADAPT trial of efgartigimod (ARG-113; argenx) in adult patients with generalized myasthenia gravis (gMG). The post Trial Assessing Efgartigimod for Myasthenia Gravis Meets Primary End Point appeared first on MPR.... Read more

Positive topline data was announced from the phase 3 ADAPT trial of efgartigimod (ARG-113; argenx) in adult patients with generalized myasthenia gravis (gMG). The post Trial Assessing Efgartigimod for Myasthenia Gravis Meets Primary End Point appeared first on MPR.... Read more

Update COVID-19 28 May 2020 gasherebukab@who.int Thu, 28/05/2020 - 20:19 28 May 2020... Read more